Ozempic Weight Loss Drug Maker Is Making Money Hand Over Fist - And Just Raised Its Profit Forecast
  • 6 months ago
Novo Nordisk (A/S NVO) raised its FY23 guidance as sales of its blockbuster obesity and weight-loss drugs continue to surge.

The success of the weight-loss drug Wegovy and diabetes treatment Ozempic has helped the Danish pharmaceutical giant surge to make it Europe's most valuable company.